Nang Kuang Pharmaceutical Co., Ltd.

TWSE:1752 Stock Report

Market Cap: NT$4.2b

Nang Kuang Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Nang Kuang Pharmaceutical has been growing earnings at an average annual rate of 3.4%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 5.1% per year. Nang Kuang Pharmaceutical's return on equity is 5.2%, and it has net margins of 5.7%.

Key information

3.4%

Earnings growth rate

3.3%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate5.1%
Return on equity5.2%
Net Margin5.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

There May Be Some Bright Spots In Nang Kuang Pharmaceutical's (TWSE:1752) Earnings

Nov 19
There May Be Some Bright Spots In Nang Kuang Pharmaceutical's (TWSE:1752) Earnings

Recent updates

There May Be Some Bright Spots In Nang Kuang Pharmaceutical's (TWSE:1752) Earnings

Nov 19
There May Be Some Bright Spots In Nang Kuang Pharmaceutical's (TWSE:1752) Earnings

Nang Kuang Pharmaceutical Co., Ltd.'s (TWSE:1752) 28% Price Boost Is Out Of Tune With Earnings

May 22
Nang Kuang Pharmaceutical Co., Ltd.'s (TWSE:1752) 28% Price Boost Is Out Of Tune With Earnings

Some Investors May Be Willing To Look Past Nang Kuang Pharmaceutical's (TWSE:1752) Soft Earnings

Apr 02
Some Investors May Be Willing To Look Past Nang Kuang Pharmaceutical's (TWSE:1752) Soft Earnings

Nang Kuang Pharmaceutical (GTSM:1752) Has A Pretty Healthy Balance Sheet

Mar 20
Nang Kuang Pharmaceutical (GTSM:1752) Has A Pretty Healthy Balance Sheet

Should You Or Shouldn't You: A Dividend Analysis on Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)

Mar 03
Should You Or Shouldn't You: A Dividend Analysis on Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)

Declining Stock and Decent Financials: Is The Market Wrong About Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)?

Feb 13
Declining Stock and Decent Financials: Is The Market Wrong About Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)?

Nang Kuang Pharmaceutical's (GTSM:1752) Stock Price Has Reduced 17% In The Past Five Years

Jan 26
Nang Kuang Pharmaceutical's (GTSM:1752) Stock Price Has Reduced 17% In The Past Five Years

Estimating The Fair Value Of Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)

Jan 08
Estimating The Fair Value Of Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)

Here's How We Evaluate Nang Kuang Pharmaceutical Co., Ltd.'s (GTSM:1752) Dividend

Nov 29
Here's How We Evaluate Nang Kuang Pharmaceutical Co., Ltd.'s (GTSM:1752) Dividend

Revenue & Expenses Breakdown

How Nang Kuang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TWSE:1752 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,137122338167
30 Jun 242,094111331169
31 Mar 242,106159332167
31 Dec 232,150198332164
30 Sep 232,235395258154
30 Jun 232,189423254149
31 Mar 232,138405242147
31 Dec 221,940352229144
30 Sep 221,789242212143
30 Jun 221,763213204140
31 Mar 221,733192203137
31 Dec 211,780196206134
30 Sep 211,758192210143
30 Jun 211,718176209146
31 Mar 211,698165213157
31 Dec 201,755183212160
30 Sep 201,826216237153
30 Jun 201,871247245147
31 Mar 201,865245241139
31 Dec 191,762217240131
30 Sep 191,674161213127
30 Jun 191,563110206136
31 Mar 191,53799214149
31 Dec 181,539101217155
30 Sep 181,564129218173
30 Jun 181,575153229161
31 Mar 181,531158222143
31 Dec 171,504186219136
30 Sep 171,420203226116
30 Jun 171,434211222119
31 Mar 171,493225228116
31 Dec 161,550225230116
30 Sep 161,608212233120
30 Jun 161,601233234113
31 Mar 161,571227232109
31 Dec 151,520199232106
30 Sep 151,46818822595
30 Jun 151,45115322096
31 Mar 151,363109212101
31 Dec 141,27767203114
30 Sep 141,21819201125
30 Jun 141,106-7195118
31 Mar 141,056-14195121

Quality Earnings: 1752 has a large one-off loss of NT$76.1M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 1752's current net profit margins (5.7%) are lower than last year (17.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1752's earnings have grown by 3.4% per year over the past 5 years.

Accelerating Growth: 1752's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 1752 had negative earnings growth (-69.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (11.9%).

Return on Equity

High ROE: 1752's Return on Equity (5.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 21:08
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nang Kuang Pharmaceutical Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhennan LeeJih Sun Securities Investment Consulting Co., Ltd.
Yuan LuKGI Securities Co. Ltd.
Xiaowei HuangMasterlink Securities Corp.